270 related articles for article (PubMed ID: 38329361)
1. Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in
Gutierrez-Gongora D; Woods M; Prosser RS; Geddes-McAlister J
Microbiol Spectr; 2024 Mar; 12(3):e0284123. PubMed ID: 38329361
[TBL] [Abstract][Full Text] [Related]
2. Differentiated extracts from freshwater and terrestrial mollusks inhibit virulence factor production in Cryptococcus neoformans.
Gutierrez-Gongora D; Raouf-Alkadhimi F; Prosser RS; Geddes-McAlister J
Sci Rep; 2023 Mar; 13(1):4928. PubMed ID: 36967422
[TBL] [Abstract][Full Text] [Related]
3. Combatting the evolution of antifungal resistance in Cryptococcus neoformans.
Bermas A; Geddes-McAlister J
Mol Microbiol; 2020 Nov; 114(5):721-734. PubMed ID: 32697029
[TBL] [Abstract][Full Text] [Related]
4. Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans.
Huang W; Liao G; Baker GM; Wang Y; Lau R; Paderu P; Perlin DS; Xue C
mBio; 2016 May; 7(3):. PubMed ID: 27165800
[TBL] [Abstract][Full Text] [Related]
5. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
6. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.
Gago S; Serrano C; Alastruey-Izquierdo A; Cuesta I; Martín-Mazuelos E; Aller AI; Gómez-López A; Mellado E
Mycoses; 2017 Jan; 60(1):40-50. PubMed ID: 27633849
[TBL] [Abstract][Full Text] [Related]
7. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
8. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
9. Coregulation of extracellular vesicle production and fluconazole susceptibility in
Rizzo J; Trottier A; Moyrand F; Coppée JY; Maufrais C; Zimbres ACG; Dang TTV; Alanio A; Desnos-Ollivier M; Mouyna I; Péhau-Arnaude G; Commere PH; Novault S; Ene IV; Nimrichter L; Rodrigues ML; Janbon G
mBio; 2023 Aug; 14(4):e0087023. PubMed ID: 37310732
[TBL] [Abstract][Full Text] [Related]
10. An Atypical ABC Transporter Is Involved in Antifungal Resistance and Host Interactions in the Pathogenic Fungus Cryptococcus neoformans.
Winski CJ; Qian Y; Mobashery S; Santiago-Tirado FH
mBio; 2022 Aug; 13(4):e0153922. PubMed ID: 35726920
[TBL] [Abstract][Full Text] [Related]
11. Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.
Wambaugh MA; Denham ST; Ayala M; Brammer B; Stonhill MA; Brown JC
Elife; 2020 May; 9():. PubMed ID: 32367801
[TBL] [Abstract][Full Text] [Related]
12. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
13. Host Carbon Dioxide Concentration Is an Independent Stress for Cryptococcus neoformans That Affects Virulence and Antifungal Susceptibility.
Krysan DJ; Zhai B; Beattie SR; Misel KM; Wellington M; Lin X
mBio; 2019 Jul; 10(4):. PubMed ID: 31266878
[TBL] [Abstract][Full Text] [Related]
14. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.
Sanguinetti M; Posteraro B; La Sorda M; Torelli R; Fiori B; Santangelo R; Delogu G; Fadda G
Infect Immun; 2006 Feb; 74(2):1352-9. PubMed ID: 16428784
[TBL] [Abstract][Full Text] [Related]
15. Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans.
Bermas A; Geddes-McAlister J
Curr Protoc Microbiol; 2020 Dec; 59(1):e116. PubMed ID: 32986290
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
[TBL] [Abstract][Full Text] [Related]
18. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.
Paul S; Doering TL; Moye-Rowley WS
Fungal Genet Biol; 2015 Jan; 74():1-9. PubMed ID: 25445311
[TBL] [Abstract][Full Text] [Related]
19. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
20. Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks.
Gutierrez-Gongora D; Raouf-Alkadhimi F; Prosser RS; Geddes-McAlister J
J Vis Exp; 2022 Dec; (190):. PubMed ID: 36533849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
